PDD-A2-73 trial and use of Actigraphy. There should be no doubt that this device and the science associated will mark a major step in CNS disease trials/studies of all type. IMO, it is only a matter of (short) time until the Precision involved in such measuring devices must be more fully recognized as critical to a proper trial. This transition will happen in spite of resistance from the PET-MRI manufacturers and clinics. Like saying goodbye to Amyloid thesis trials.
Keep in mind the PDD trail has (secondary) trial criteria where Actigraphy is in use providing instantaneous, accurate and directly objective sleep quality data. This data will.may be correlated to historical analog type methods allowing retrospective validation techniques as well as the building of a new body of knowledge.
Market Data 
Markets 
AI
